Gilead Sciences (GILD) Asset Utilization Ratio (2009 - 2026)
Gilead Sciences' (GILD) quarterly Asset Utilization Ratio came in at 0.52 in Q1 2026, up 3.6% YoY from 0.5 in Q1 2025, and up 2.97% on a QoQ basis from 0.5 in Q4 2025.
Gilead Sciences (GILD) Asset Utilization Ratio (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Asset Utilization Ratio data on file, last reported at 0.52 in Q1 2026.
- Quarterly Asset Utilization Ratio rose 3.6% year-over-year to 0.52 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.52 (up 3.6% YoY) and the FY2025 annual result came in at 0.5, up 5.09% from the prior year.
- Asset Utilization Ratio rose to 0.52 in Q1 2026, from 0.5 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.52 in Q3 2024 to a low of 0.42 in Q1 2022.
- A 5-year average of 0.47 and a median of 0.46 in 2024 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2024 — Asset Utilization Ratio increased 19.19% — and 2025, when it slipped 2.75%.
- Tracing GILD's Asset Utilization Ratio over 5 years: stood at 0.43 in 2022, then increased by 0.38% to 0.44 in 2023, then increased by 16.3% to 0.51 in 2024, then slipped by 1.12% to 0.5 in 2025, then gained by 2.97% to 0.52 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.52 (Q1 2026), 0.5 (Q4 2025), and 0.51 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.03 Bn | 632.27 Bn | 17.26 Bn | 0.49 |
| 2 | AbbVie | 469.62 Bn | 463.05 Bn | 12.70 Bn | 0.47 |
| 3 | Merck | 375.00 Bn | 367.85 Bn | 12.21 Bn | 0.52 |
| 4 | Novartis Ag | 303.31 Bn | 295.62 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.68 Bn | 252.78 Bn | 12.86 Bn | 0.53 |
| 6 | Amgen | 236.34 Bn | 222.35 Bn | 7.24 Bn | 0.40 |
| 7 | Gilead Sciences | 182.09 Bn | 178.91 Bn | 6.22 Bn | 0.58 |
| 8 | Pfizer | 159.43 Bn | 147.73 Bn | 10.94 Bn | 0.31 |
| 9 | Gsk | 106.25 Bn | 102.08 Bn | 8.24 Bn | 0.64 |
| 10 | Sanofi | 55.19 Bn | 47.81 Bn | 10.79 Bn | 0.36 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.58 |
| Mar 31, 2026 | 0.52 |
| Dec 31, 2025 | 0.50 |
| Sep 30, 2025 | 0.51 |
| Jun 30, 2025 | 0.51 |
| Mar 31, 2025 | 0.50 |
| Dec 31, 2024 | 0.51 |
| Sep 30, 2024 | 0.52 |
| Jun 30, 2024 | 0.51 |
| Mar 31, 2024 | 0.46 |
| Dec 31, 2023 | 0.44 |
| Sep 30, 2023 | 0.44 |
| Jun 30, 2023 | 0.44 |
| Mar 31, 2023 | 0.43 |
| Dec 31, 2022 | 0.43 |
| Sep 30, 2022 | 0.43 |
| Jun 30, 2022 | 0.44 |
| Mar 31, 2022 | 0.42 |
| Dec 31, 2021 | 0.40 |
| Sep 30, 2021 | 0.41 |